Ghisallo Capital Management’s Century Therapeutics IPSC Stock Holding History

Ghisallo Capital Management’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15,000	Closed	-$377K	–	489
2021 Q3	$377K	Sell	15,000 -15,000	-50%	-$406K	0.01%	414
2021 Q2	$880K	Buy	+30,000	New	+$761K	0.03%	366

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Ghisallo Capital Management's IPSC Position: Q4 2021 in Review

Ghisallo Capital Management sold out of Century Therapeutics (IPSC) in Q4 2021, closing a stake of 15,000 shares — an estimated $377K sold.

Ghisallo Capital Management first reported a position in IPSC in Q2 2021 and held it in 2 quarters. The position peaked at $880K in Q2 2021. 50 funds tracked by Wall St. Rank hold IPSC as of Q4 2021.

Ghisallo Capital Management reported no remaining Century Therapeutics position as of Q4 2021 after selling out during the quarter.
Ghisallo Capital Management sold 15,000 Century Therapeutics shares in Q4 2021, an estimated $377K.
Ghisallo Capital Management first reported a position in Century Therapeutics in Q2 2021 and held it in 2 quarters.
Ghisallo Capital Management's Century Therapeutics position peaked at $880K in Q2 2021.
50 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2021.

Based on Ghisallo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.